Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IUPUI chemists develop Distributed Drug Discovery: Finding drugs for neglected diseases

17.06.2009
Researchers from Indiana University-Purdue University Indianapolis (IUPUI) have developed Distributed Drug Discovery (D3), a new low-cost strategy to accelerate the discovery of drugs to treat neglected diseases such as tuberculosis, leprosy, leshmaniasis, dengue fever, and Chagas disease.

Even in times of economic prosperity, the pharmaceutical industry has often been reluctant to get involved in developing treatments for diseases that occur primarily in low income countries. The low cost D3 approach, involving distributed global educational resources at the early stage of discovery, is even more attractive in this time of global economic downturn.

A distributed problem solving process breaks large problems into small pieces which are "distributed" to multiple, small, low-cost sites to obtain a solution. For decades astronomers have enlisted the help of the public, asking individuals around the world to leave their home computers on overnight. While normally idle, each one of these computers looks for patterns in a small subset of the incredibly large amount of space noise signals received by arrays of radio telescopes scanning the skies.

Two studies, published this year in the Journal of Combinatorial Chemistry, detail the first two steps in D3, developed by William Scott, Ph.D., research professor, and Martin J. O'Donnell, Ph.D., IUPUI Chancellor's Professor, both of the Department of Chemistry and Chemical Biology at IUPUI.

D3 uses a distributed problem approach at all three key stages of drug discovery. Step one is identifying candidate drug molecules. To do this, IUPUI researchers are soliciting the global advice of computational experts in neglected disease areas and utilizing the computational power of multiple personal computers around the world to scan the almost infinite number of molecules which the D3 synthesis process could make to identify the smaller number of drug candidate molecules they should make. Dr. Scott and Dr. O'Donnell believe this will lead to the selection, synthesis and development of innovative and inexpensive drugs to treat these neglected diseases.

In the second step, D3 uses an innovative, distributed educational approach to synthesize the candidate molecules. Undergraduate and graduate chemistry students from around the world synthesize subsets of these candidate molecules as part of their normal training in synthetic chemistry. Currently students at IUPUI, the University of Indianapolis, and universities in Poland, Russia and Spain have demonstrated their ability to make the molecules (or portions of the molecules) that can be identified by the personal computers as potential candidates for drug discovery.

Initial results are very promising, according to Dr. Scott. "While learning chemistry synthesis skills students across the globe synthesize new molecules to be tested as drug leads. The molecules meet the same quality standards as those required in industry. At the same time the students enthusiastically participate in the synthesis laboratories. They enjoy seeing how their work will advance science that is going to make a difference to individuals suffering from diseases which have been ignored," he said.

The third step in D3 is biological testing of the molecules synthesized by the students. Dr. Scott and Dr. O'Donnell hope the success of distributed problem solving at the computational and synthetic stages of drug discovery will encourage their biological colleagues to develop simple, inexpensive tests to enable students worldwide to participate in this final stage of drug-lead discovery. Currently some of the molecules made are being evaluated through the resources of the National Institutes of Health. In the future, promising drugs will then go on to pre-clinical trials.

"The coordinated and recombined results of these distributed D3 resources can economically accelerate the identification of leads in the early stages of the drug discovery process. Simultaneously, this effort provides educational and job opportunities in both the developed and developing worlds, while building cultural and economic bridges for the common good," Dr. Scott and Dr. O'Donnell wrote in an accompanying perspective article.

The studies on D3 published in the Journal of Combinatorial Chemistry were funded by the National Institutes of Health, National Science Foundation, Camille and Henry Dreyfus Foundation, and Lilly Research Laboratories.

Dr. Scott and Dr. O'Donnell continue to enlist chemistry departments in the United States and other parts of the globe in this program to help children and adults with devastating diseases which have been largely ignored by the developed world.

Cindy Fox Aisen | EurekAlert!
Further information:
http://www.iupui.edu

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>